Finnish is available via eTranslation, the European Commission's machine translation service.
Translate to Finnish | Important information about machine translation
Ajankohta
Sijainti
This joint HMA / EMA hybrid workshop is anchored in the Network Data Steering Group workplan and follows stakeholders’ interactions to support medicines regulation and access in the field of Duchenne muscular dystrophy (DMD).
Drug development in DMD remains complex. Despite existing and past efforts on several levels, the challenges persist. They include generation of relevant and high-quality evidence to support regulatory decisions - as defined in the Data Quality Framework for EU medicines regulation: application to Real-World Data.
This workshop, supported by the World Duchenne Organization, aims to discuss current gaps and hurdles in data collection, and to explore how we can all collaborate to enable the generation of meaningful evidence on the effectiveness and safety of medicines.
The event brings together representatives from patient organisations, regulatory agencies, healthcare professional organisations, data holders, academia, non-for-profit research institutions, pharmaceutical companies, health technology assessment bodies and payers with the following objectives:
Complete the Teams registration form to request in-person or online participation.
A video recording of the plenary sessions will be available after the event.